Brian’s Story: Finding a Treatment for Type 1 Gaucher

By National Gaucher FoundationNov 25, 2016

This post is sponsored content. The Forward’s editorial staff were not involved in its publication.

Brian Berman is president and chief executive officer of the National Gaucher Foundation (NGF). Diagnosed at the age of 4 with Type 1 Gaucher disease after suffering critical and worsening symptoms, Mr. Berman’s initial prognosis was grim. His parents refused to watch their son die without a fight. They found Dr. Roscoe Brady, who was then leading groundbreaking research on Gaucher disease treatment. Mr. Berman, an ideal clinical trial candidate, became the first person in the world to successfully receive enzyme replacement therapy for Gaucher disease.

The National Gaucher Foundation (NGF) is an independent nonprofit organization that serves U.S. patients with Gaucher disease and their families.

A message from our Publisher & CEO Rachel Fishman Feddersen

I hope you appreciated this article. Before you go, I’d like to ask you to please support the Forward’s award-winning, nonprofit journalism so that we can be prepared for whatever news 2025 brings.

Now more than ever, American Jews need independent news they can trust, with reporting driven by truth, not ideology. We serve you, not any ideological agenda.

At a time when other newsrooms are closing or cutting back, the Forward has removed its paywall and invested additional resources to report on the ground from Israel and around the U.S. on the impact of the war, rising antisemitism and polarized discourse.

Readers like you make it all possible. Support our work by becoming a Forward Member and connect with our journalism and your community.

— Rachel Fishman Feddersen, Publisher and CEO